Mesa Laboratories Inc

Industrials
Industrial Machinery/Components
www.mesalabs.com

Earnings Score
Moat Score
Safety Score

Market Cap $643.61M
PE -3
Debt $169.35M
Cash $30.96M
EV $782.00M
FCF $43.00M

Earnings

loading chart...

Sales & Net Margins

loading chart...

Earnings	-$249.44M
EBIT	-$256.89M
ROE	-161%
ROA	-59%
FCF	$43.00M
Equity	$155.21M
Growth Stability	-13K%
PE	-2.58
PEG	0.81
PB	4.15
P/FCF	14.97
P/S	2.71
Price/Cash	0.05
Debt/Equity	1.09
Debt/FCF	3.94
Net Margins	3%
Gross Margins	63%
Op. Margins	-108%
Earnings CAGR	-5%
Sales Growth YoY	18%
Sales Growth QoQ	9%
Sales CAGR	14%
FCF CAGR	18%
Equity CAGR	18%
Earnings Stability	0.11
Earnings Growth YoY	-179%
Earnings Growth QoQ	-149%
Earnings CAGR 5Y	-3%

Sales CAGR 5Y	17%
FCF CAGR 5Y	6%
Equity CAGR 5Y	-14%
Earnings CAGR 3Y	5%
Sales CAGR 3Y	5%
FCF CAGR 3Y	22%
Equity CAGR 3Y	-33%
Market Cap	$643.61M
Revenue	$237.75M
Dividend Yield	1%
Payout Ratio	-1%
Assets	$437.15M
Total Debt	$169.35M
Cash	$30.96M
Shares Outstanding	5.41M
EV	782M
Earnings Score	5%
Moat Score	23%
Safety Score	55%
Final Score	28%
Working Capital	-45.03M
Current Ratio	0.71
Gross Profit	$149.01M
Shares Growth 3y	1%
Equity Growth QoQ	-4%
Equity Growth YoY	-61%

Assets & ROA

loading chart...

Stockholders Equity & ROE

loading chart...

Mesa Laboratories Inc manufactures life sciences tools and critical quality control products. It operates in 4 divisions: Sterilization & Disinfection Control, which manufactures and sells biological, cleaning, and chemical indicators. It also provides testing and laboratory services, mainly to the dental industry; Biopharmaceutical Development segment develops, manufactures, and sells automated systems for protein analysis (immunoassays) and peptide synthesis solutions; Calibration Solutions division develops, manufactures, and sells quality control and calibration products used to measure or calibrate temperature, pressure, pH, humidity, and other such parameters for health and safety purposes; and Clinical Genomics. Its geographical segments include United States and Foreign.

SEC Filings

Direct access to Mesa Laboratories Inc (MLAB) Annual Reports (10K) and Quarterly Reports (10Q) from the SEC website.

2024
- 10-Q Dec 31
- 10-Q Sep 30
- 10-Q Jun 30
- 10-K Mar 31
2023
- 10-Q Dec 31
- 10-Q Sep 30
- 10-Q Jun 30
- 10-K Mar 31
2022
- 10-Q Dec 31
- 10-Q Sep 30
- 10-Q Jun 30
- 10-K Mar 31

Sector Comparison

How does Mesa Laboratories Inc compare to its competitors?

Loading chart...

Peter Lynch's Chart

This chart shows the current pricing of Mesa Laboratories Inc compared to its past. The addition of the earnings trend line provides further insights into the company's earnings power.

CAGR -5%

Stability 11%

loading chart...

Mesa Laboratories Inc Discounted Cash Flow

Fully customizable DCF calculator online for Mesa Laboratories Inc .

Years

Calculation mode

= $1.5B

	0	1	2	3	4	5	6	7	8	9	10	TV
fcf	$43M	$51M	$60M	$71M	$83M	$99M	$116M	$137M	$162M	$191M	$226M	$2.3B
DCF		$46M	$50M	$53M	$57M	$61M	$66M	$70M	$76M	$81M	$87M	$871M
Value	$1.5B

Competitiveness and MOAT

High margins render the company resilient under dire circumstances, hence able to drive competitors out or acquire them. ROE and ROA measure the average flow generated by each invested dollar. Their marginal value is a forecast of future growth, and it is considered by Buffett and Munger the most important single indicator.

Years	03/2016	03/2017	03/2018	03/2019	03/2020	03/2021	03/2022	03/2023	03/2024	TTM
Net Margins	13%	12%	-3%	7%	1%	2%	1%	0%	-118%	3%
ROA	-	9%	1%	7%	2%	2%	1%	1%	-61%	-59%
ROE	-	11%	-3%	7%	1%	1%	0%	0%	-175%	-161%

Bad Net Margins (2.87%)

Net Margins are too low to guarantee profitability in case of higher costs or higher interest rates. Furthermore lower margins cause higher earnings’ volatility.

Safety and Stability

Being debt the number one cause of investment losses and company death, the ratio Debt/FCF is of utmost importance to guarantee safety. On the other hand the Graham’s stability measures the drawdown of earnings, hence indicating the reliability of the flow generated by the company.

Years	03/2016	03/2017	03/2018	03/2019	03/2020	03/2021	03/2022	03/2023	03/2024	TTM
Debt over FCF	-	-14.62	2.12K	0.86	5.6	4.15	4.87	7.26	4.12	3.94
Debt over Equity	0.57	0.58	469.26	0.23	0.64	0.36	0.43	0.43	1.18	1.09
Growth Stability	-	-	-	100%	26%	100%	46%	43%	-13K%	-13K%

Neutral Debt/FCF ratio (3.94)

Net Margins are at a level that is not too high nor too low. They are not a competitive advantage but they are not a competitive disadvantage either.

Neutral Debt/Equity ratio (1.09)

The company has a balance between equity and debt that is not too good nor too bad.

Bad Graham’s Stability (-13K%)

The company has a bad stability in its earnings, which is a sign of a bad competitive advantage.

Growth

Growth can be dangerous when forecasting, simply projecting the current growth is in general wrong. A company passes through multiple phases, from being young and unprofitable, to the first periods of profitability and high growth, until it arrives at a period of regime with limited growth. Identifying in which phase the company is in may help forecasting.

Years	03/2016	03/2017	03/2018	03/2019	03/2020	03/2021	03/2022	03/2023	03/2024	CAGR 5Y
Revenue YoY growth	-	11%	3%	7%	14%	14%	38%	19%	-1%	17%
Earnings YoY growth	-	0%	-126%	-353%	-82%	143%	-43%	-50%	-27K%	-3%
Equity YoY growth	-	16%	2%	12%	98%	85%	-3%	-0%	-63%	-14%
FCF YoY growth	-	-142%	-671%	33%	-14%	40%	-1%	-33%	77%	6%